共 50 条
- [21] Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy AdultsINFECTIOUS DISEASES AND THERAPY, 2023, 12 (05) : 1365 - 1377Schmidt, PeteGong, JeanNarayan, KristinGupta, DeepaliEngler, FrankLi, YongCopans, AmandaCampanaro, Ed
- [22] Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy AdultsInfectious Diseases and Therapy, 2023, 12 : 1365 - 1377Pete SchmidtJean GongKristin NarayanDeepali GuptaFrank EnglerYong LiAmanda CopansEd Campanaro
- [23] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111Gottlieb, AliceDeodhar, AtulBoehncke, Wolf-HenningDong, BinWang, YuhuaBarchuk, WilliamHsia, Elizabeth
- [24] Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's DiseaseINFLAMMATORY BOWEL DISEASES, 2010, 16 (10) : 1708 - 1716van der Woude, C. JannekeStokkers, PieterVan Bodegraven, Ad A.Van Assche, GertHebzda, ZbigniewParadowski, LeszekD'Haens, GeertGhosh, SubrataFeagan, BrianRutgeerts, PaulDijkstra, Gerardde Jong, Dirk J.Oldenburg, BasFarhan, MahdiRichard, TristanDean, YannHommes, Daniel W.
- [25] A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Intravenous Dose Study of a novel TREM2 agonist (VGL101) in Healthy Volunteers (HVs)NEUROLOGY, 2023, 100 (17)Papapetropoulos, SpyridonMeier, AndreasO'Mara, RyanMarsh, AndrewNeelon, KellyRajagovindan, RajasimhanThackaberry, EvanStiles, David
- [26] Safety, Tolerability and Pharmacokinetics of GSK3389404, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B (CHB) Infection: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human StudyHEPATOLOGY, 2017, 66 : 490A - 491AHan, KelongKim, JenniferElston, RobOliver, StuartBaptiste-Brown, SharonChen, ShuguangLahiri, SoumiGardiner, DavidDavies, Mattvan den Berg, FransPaff, MelaniTheodore, Dickens
- [27] A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple MyelomaBLOOD, 2017, 130Brighton, TimothyHarrison, Simon J.Ghez, DavidWeiss, Brendan M.Kirsch, AndreasMagen, HilaGironella, MercedesOriol, AlbertStreetly, MatthewQin, XiangBandekar, RajeshHu, PeterQi, MingNemat, SepidehGoldschmidt, Hartmut
- [28] A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS']JS005 in Patients with Moderate to Severe PsoriasisARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3809 - 3811Cai, LinMu, ZhangleiTao, XiaohuaZhang, LitaoZhang, ChunleiLi, YumeiZhang, GuoqiangZhang, FurenDong, XiuqinLi, ChengxinChen, AijunWu, ZhuningZhu, YuxianZhang, MengqiLiu, JiangnianZhang, Jianzhong
- [29] TOLERABILITY, SAFETY, AND PHARMACOKINETICS OF THE NOVEL PDE INHIBITOR ZSP1601 IN HEALTHY SUBJECTS: A DOUBLE-BLIND, PLACEBO-CONTROLLED FIRST-IN-HUMAN SINGLE-DOSE, MULTIPLE-DOSE ESCALATION AND FOOD EFFECT STUDYHEPATOLOGY, 2019, 70 : 1360A - 1361ALi, CuiyunZhang, HongZhu, XiaoxueWu, MinHu, YueLi, XiaojiaoLi, HaijunChen, XiaoxinPeng, YunDing, Hua YanNiu, Junqi
- [30] First-in-Human Study of REGN668/SAR231893 (IL-4Rα mAb): Safety, Tolerability and Biomarker Results of a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy VolunteersJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB158 - AB158Radin, AllenRen, HaoboPapino-Wood, PamelaChaudhry, UsmanHamilton, Jennifer D.